| Name | SCH-23390 hydrochloride |
| Description | SCH-23390 hydrochloride (R-(+)-SCH23390 hydrochloride) is an effective dopamine receptor antagonist, with high affinity for the D1 (Ki=0.2 nM) and D5 (Ki=0.3 nM) receptors. |
| Animal Research | Rats are injected with SCH 23390(0, 1, or 10 μg/kg i.p.). |
| In vitro | SCH23390 blocks endogenous GIRK currents induced by either somatostatin or D3 dopamine receptors in AtT-20 cells (IC50=268 nM).SCH 23390 also shows high affinity (Ki=9.3 nM) at h5-HT2C sites. |
| In vivo | In the rat, the repeated administration of SCH 23390 (0.05 mg/kg s.c., thrice daily for 21 days) enhances the steady-state density of dopamine D1 receptors in the striatum (+30%) and substantia nigra (+24%). |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 25 mg/mL (77.1 mM), Sonication is recommended. DMSO : 50 mg/mL (154.21 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.17 mM), Sonication is recommended.
|
| Keywords | SCH-23390 Hydrochloride | R-SCH-23390 Hydrochloride | R-SCH23390 Hydrochloride | R-SCH 23390 Hydrochloride | PotassiumChannel | Potassium Channel | DopamineReceptor | Dopamine Receptor | Dopamine | D5 | D1 | 5HTReceptor | 5-HT Receptor | 5HT Receptor |
| Inhibitors Related | Alverine citrate | Dapoxetine hydrochloride | Cefaclor monohydrate | Hexamethonium Bromide | Hydrochlorothiazide | 1,8-Cineole | Tetraethylammonium bromide | Ursodeoxycholic acid | Chenodeoxycholic acid | Chlorzoxazone | Cinchonidine | Indapamide |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Parkinson's Disease Compound Library | Angiogenesis related Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Potassium Channel Targeted Library | GPCR Compound Library | Ion Channel Targeted Library |